| Title |
Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature
|
|---|---|
| Published in |
Biologics: Targets & Therapy, April 2016
|
| DOI | 10.2147/btt.s102954 |
| Pubmed ID | |
| Authors |
Jeroen CH van der Hilst, Michel Moutschen, Peter E Messiaen, Bernard R Lauwerys, Steven Vanderschueren |
| Abstract |
In 5%-10% of patients with familial Mediterranean fever (FMF), colchicine is not effective in preventing inflammatory attacks. Another 5%-10% of patients are intolerant to effective doses of colchicine and experience serious side effects. Treatment with anti-interleukin-1 (IL-1) drugs may be an alternative for these patients, although it is not reimbursed for this indication in many countries. We systematically searched PubMed, Web of Science, and Scopus for reports of anti-IL-1 treatment in FMF patients. Out of 284 potentially relevant articles, 27 eligible reports were identified and included in the data analysis. A complete response to therapy without a single attack during treatment was reported in 76.5% of patients on anakinra treatment and in 67.5% of patients during canakinumab treatment. In patients with established type AA amyloidosis, anti-IL-1 treatment can reverse proteinuria. Anti-IL-1 therapy seems to be a safe and effective alternative for patients with FMF who do not respond to or cannot tolerate colchicine. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 1 | 33% |
| Argentina | 1 | 33% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 62 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 9 | 15% |
| Student > Bachelor | 7 | 11% |
| Researcher | 7 | 11% |
| Professor | 5 | 8% |
| Student > Master | 5 | 8% |
| Other | 13 | 21% |
| Unknown | 16 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 42% |
| Biochemistry, Genetics and Molecular Biology | 8 | 13% |
| Agricultural and Biological Sciences | 2 | 3% |
| Psychology | 2 | 3% |
| Immunology and Microbiology | 2 | 3% |
| Other | 3 | 5% |
| Unknown | 19 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 October 2020.
All research outputs
#4,947,179
of 25,806,080 outputs
Outputs from Biologics: Targets & Therapy
#57
of 286 outputs
Outputs of similar age
#71,306
of 315,696 outputs
Outputs of similar age from Biologics: Targets & Therapy
#2
of 6 outputs
Altmetric has tracked 25,806,080 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 286 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 315,696 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.